ACURX PHARMACEUTICALS INC (ACXP) Stock Price & Overview
NASDAQ:ACXP • US00510M2035
The current stock price of ACXP is 5.01 USD. Today ACXP is down by -16.92%. In the past month the price increased by 192.72%. In the past year, price decreased by -34.6%.
ACXP Key Statistics
- Market Cap
- 12.776M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.52
- Dividend Yield
- N/A
ACXP Stock Performance
ACXP Stock Chart
ACXP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ACXP. When comparing the yearly performance of all stocks, ACXP turns out to be only a medium performer in the overall market: it outperformed 58.72% of all stocks.
ACXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACXP. ACXP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACXP Earnings
ACXP Forecast & Estimates
9 analysts have analysed ACXP and the average price target is 62.93 USD. This implies a price increase of 1156.17% is expected in the next year compared to the current price of 5.01.
ACXP Groups
Sector & Classification
ACXP Financial Highlights
Over the last trailing twelve months ACXP reported a non-GAAP Earnings per Share(EPS) of -8.52. The EPS increased by 60.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.2% | ||
| ROE | -252.13% | ||
| Debt/Equity | 0 |
ACXP Ownership
ACXP Latest News, Press Relases and Analysis
ACXP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 402.577B | ||
| AMGN | AMGEN INC | 16.11 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.5 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACXP
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
Company Info
IPO: 2021-06-25
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK US
CEO: David P. Luci
Employees: 4
Phone: 19175331469
ACURX PHARMACEUTICALS INC / ACXP FAQ
What does ACURX PHARMACEUTICALS INC do?
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.
What is the current price of ACXP stock?
The current stock price of ACXP is 5.01 USD. The price decreased by -16.92% in the last trading session.
Does ACURX PHARMACEUTICALS INC pay dividends?
ACXP does not pay a dividend.
How is the ChartMill rating for ACURX PHARMACEUTICALS INC?
ACXP has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ACXP stock?
ACURX PHARMACEUTICALS INC (ACXP) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ACXP stock?
ACURX PHARMACEUTICALS INC (ACXP) has a market capitalization of 12.78M USD. This makes ACXP a Nano Cap stock.